Literature DB >> 22687511

Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276.

Krisztina M Papp-Wallace1, Magdalena A Taracila, Kerri M Smith, Yan Xu, Robert A Bonomo.   

Abstract

β-Lactamases are important antibiotic resistance determinants expressed by bacteria. By studying the mechanistic properties of β-lactamases, we can identify opportunities to circumvent resistance through the design of novel inhibitors. Comparative amino acid sequence analysis of class A β-lactamases reveals that many enzymes possess a localized positively charged residue (e.g., R220, R244, or R276) that is critical for interactions with β-lactams and β-lactamase inhibitors. To better understand the contribution of these residues to the catalytic process, we explored the roles of R220 and E276 in KPC-2, a class A β-lactamase that inactivates carbapenems and β-lactamase inhibitors. Our study reveals that substitutions at R220 of KPC-2 selectively impact catalytic activity toward substrates (50% or greater reduction in k(cat)/K(m)). In addition, we find that residue 220 is central to the mechanism of β-lactamase inhibition/inactivation. Among the variants tested at Ambler position 220, the R220K enzyme is relatively "inhibitor susceptible" (K(i) of 14 ± 1 μM for clavulanic acid versus K(i) of 25 ± 2 μM for KPC-2). Specifically, the R220K enzyme is impaired in its ability to hydrolyze clavulanic acid compared to KPC-2. In contrast, the R220M substitution enzyme demonstrates increased K(m) values for β-lactamase inhibitors (>100 μM for clavulanic acid versus 25 ± 3 μM for the wild type [WT]), which results in inhibitor resistance. Unlike other class A β-lactamases (i.e., SHV-1 and TEM-1), the amino acid present at residue 276 plays a structural rather than kinetic role with substrates or inhibitors. To rationalize these findings, we constructed molecular models of clavulanic acid docked into the active sites of KPC-2 and the "relatively" clavulanic acid-susceptible R220K variant. These models suggest that a major 3.5-Å shift occurs of residue E276 in the R220K variant toward the active S70 site. We anticipate that this shift alters the shape of the active site and the positions of two key water molecules. Modeling also suggests that residue 276 may assist with the positioning of the substrate and inhibitor in the active site. These biochemical and molecular modeling insights bring us one step closer to understanding important structure-activity relationships that define the catalytic and inhibitor-resistant profile of KPC-2 and can assist the design of novel compounds.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22687511      PMCID: PMC3421566          DOI: 10.1128/AAC.05769-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance.

Authors:  Jodi M Thomson; Anne M Distler; Fabio Prati; Robert A Bonomo
Journal:  J Biol Chem       Date:  2006-06-27       Impact factor: 5.157

2.  The structure of beta-lactamases.

Authors:  R P Ambler
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1980-05-16       Impact factor: 6.237

3.  Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae.

Authors:  H Yigit; A M Queenan; G J Anderson; A Domenech-Sanchez; J W Biddle; C D Steward; S Alberti; K Bush; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

4.  Elucidation of the role of arginine-244 in the turnover processes of class A beta-lactamases.

Authors:  G Zafaralla; E K Manavathu; S A Lerner; S Mobashery
Journal:  Biochemistry       Date:  1992-04-21       Impact factor: 3.162

Review 5.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

6.  Inhibition of TEM-2 beta-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry.

Authors:  R P Brown; R T Aplin; C J Schofield
Journal:  Biochemistry       Date:  1996-09-24       Impact factor: 3.162

7.  Interactions between non-classical beta-lactam compounds and the beta-lactamases of Actinomadura R39 and Streptomyces albus G.

Authors:  J A Kelly; J M Frère; C Duez; J M Ghuysen
Journal:  Biochem J       Date:  1981-10-01       Impact factor: 3.857

8.  Arginine 220 is a critical residue for the catalytic mechanism of the Streptomyces albus G beta-lactamase.

Authors:  F Jacob-Dubuisson; J Lamotte-Brasseur; O Dideberg; B Joris; J M Frère
Journal:  Protein Eng       Date:  1991-10

9.  Crystal structures of KPC-2 β-lactamase in complex with 3-nitrophenyl boronic acid and the penam sulfone PSR-3-226.

Authors:  Wei Ke; Christopher R Bethel; Krisztina M Papp-Wallace; Sundar Ram Reddy Pagadala; Micheal Nottingham; Daniel Fernandez; John D Buynak; Robert A Bonomo; Focco van den Akker
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

10.  Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A beta-lactamase isolated from Escherichia coli.

Authors:  Y Ishii; A Ohno; H Taguchi; S Imajo; M Ishiguro; H Matsuzawa
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

View more
  31 in total

Review 1.  A Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes.

Authors:  Alain Philippon; Patrick Slama; Paul Dény; Roger Labia
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

2.  Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.

Authors:  Krisztina M Papp-Wallace; Marisa L Winkler; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

3.  Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.

Authors:  David E Ehmann; Haris Jahic; Philip L Ross; Rong-Fang Gu; Jun Hu; Thomas F Durand-Réville; Sushmita Lahiri; Jason Thresher; Stephania Livchak; Ning Gao; Tiffany Palmer; Grant K Walkup; Stewart L Fisher
Journal:  J Biol Chem       Date:  2013-08-02       Impact factor: 5.157

4.  Insights into β-lactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants.

Authors:  Krisztina M Papp-Wallace; Magdalena A Taracila; Julian A Gatta; Nozomi Ohuchi; Robert A Bonomo; Michiyoshi Nukaga
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

5.  Avibactam and inhibitor-resistant SHV β-lactamases.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

6.  Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis.

Authors:  Peter S Levitt; Krisztina M Papp-Wallace; Magdalena A Taracila; Andrea M Hujer; Marisa L Winkler; Kerri M Smith; Yan Xu; Michael E Harris; Robert A Bonomo
Journal:  J Biol Chem       Date:  2012-07-26       Impact factor: 5.157

7.  Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.

Authors:  Melissa D Barnes; Magdalena A Taracila; Caryn E Good; Saralee Bajaksouzian; Laura J Rojas; David van Duin; Barry N Kreiswirth; Michael R Jacobs; Andreas Haldimann; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

8.  Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen.

Authors:  Krisztina M Papp-Wallace; Scott A Becka; Magdalena A Taracila; Elise T Zeiser; Julian A Gatta; John J LiPuma; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

9.  Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.

Authors:  Marisa L Winkler; Elizabeth A Rodkey; Magdalena A Taracila; Sarah M Drawz; Christopher R Bethel; Krisztina M Papp-Wallace; Kerri M Smith; Yan Xu; Jeffrey R Dwulit-Smith; Chiara Romagnoli; Emilia Caselli; Fabio Prati; Focco van den Akker; Robert A Bonomo
Journal:  J Med Chem       Date:  2013-02-04       Impact factor: 7.446

10.  Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase.

Authors:  Krisztina M Papp-Wallace; Scott A Becka; Magdalena A Taracila; Marisa L Winkler; Julian A Gatta; Drew A Rholl; Herbert P Schweizer; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.